Adgero is a biopharmaceutical company that develops photodynamic therapeutics for the treatment of cutaneous oncology indications... Read more
Adgero is a biopharmaceutical company that develops photodynamic therapeutics for the treatment of cutaneous oncology indications... Read more
Interim-CEO
John Liatos
News
Aug 20, 2020
BioSpace
Adgero: Kintara Therapeutics (Formerly DelMar Pharmaceuticals) Announces Completion of Merger with Adgero Biopharmaceuticals and Closing of $19.6 Million Private Placement Priced At-The-Market
Aug 17, 2020
BioSpace
Adgero: DelMar Announces Approval of Merger by Stockholders
Jul 17, 2020
MarketScreener
Adgero: DelMar Pharmaceuticals to Host Conference Call to Discuss Proposed Acquisition of Adgero Pharmaceuticals
Jun 11, 2020
Contract Pharma
Adgero: DelMar Pharma to Acquire Adgero Biopharma
Jun 10, 2020
Law.com
Press Release: Adgero : DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
Jun 10, 2020
FirstWord Pharma
Adgero: DelMar to Acquire Adgero Biopharmaceuticals, Expands Late-Stage Oncology Pipeline
Aug 08, 2018
BioPortfolio
Adgero: Adgero Biopharmaceuticals Holdings Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 12042018 Prices from USD $250
Feb 22, 2018
Marketwired
Press Release: Adgero : Adgero Biopharmaceuticals Granted FDA Orphan Drug Designation of REM-001 Therapy for the Treatment of Basal Cell Carcinoma Nevus Syndrome
Dec 13, 2017
BioPortfolio
Adgero: Adgero Biopharmaceuticals Holdings Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 27112017 Prices from USD $250
Oct 27, 2017
cfomoves
Adgero: Adgero Biopharmaceuticals Holdings, Inc. [PRINCETON, NJ] announced that it has appointed John Liatos as its Chief Financial Officer ("CFO").
